TISSUE DONATION IS CRITICAL TO FIND TREATMENTS! Click here to learn more.
We envision a world where Epithelioid Hemangioendothelioma (EHE) is easily diagnosed and treatable. Join our dedicated community by subscribing to our emails.
EMPOWER YOURSELF WITH KNOWLEDGE
Upcoming Foundation Events
Quick Links
Patients
Community
Latest EHE News, Events and Research
Advancing our Mission, Representing EHE Patients at ASCO 2024
Our Interim Executive Director and Director of Research, Denise Robinson, recently represented epithelioid hemangioendothelioma (EHE) patients at the 2024 ASCO Annual Meeting in Chicago, Illinois, where nearly 40,000 global oncology professionals convened. The American Society of Clinical Oncology (ASCO), is the world’s leading organization for oncology, bringing together advocates, healthcare providers, and related professionals to […]
Read More
Reflecting on Success: 2024 EHE Fun Run & Walk Recap
With enthusiasm and gratitude, The EHE Foundation is proud to celebrate another successful year of the Annual EHE Fun Run & Walk. This event, dedicated to supporting The EHE Foundation’s mission to find treatments and a cure for epithelioid hemangioendothelioma (EHE), always brings our community together in an extraordinary way! With 1387 registrations, our hearts […]
Read More
Planting Seeds for Future Developments: EHEF Research Grant Grows
The EHE Foundation invests in novel EHE research yearly through its EHE Research Grants Program. The program officially began in 2021, with only a few applicants interested in EHE research. Today, 10 applicants have submitted proposals in our 2024 grants cycle. Along the way, we have had the good fortune to meet and collaborate with […]
Read More
Ikena Oncology IK-930 Update
On May 28, 2024, Ikena Oncology announced they are discontinuing the development of IK-930. We share your frustration and disappointment and understand the devastating impact felt by patients. Following this announcement, we met with Ikena to impress upon them the urgency and importance that patients deriving benefits from IK-930 continue to have access to the […]
Read More
Navigating the Mental Health Challenges of an EHE Diagnosis and Treatment
Updated: April 18, 2025 A cancer diagnosis can be one of the most daunting experiences in life, not just physically, but mentally and emotionally as well. The journey through diagnosis, treatment, and everything in between often feels like a roller coaster, filled with uncertainty, fear, and a range of intense emotions. It’s essential to acknowledge […]
Read More
The Pledge: Edition 36, Q1 – January-March, 2024
Publication of The Pledge quarterly newsletter is led by the EHE Rare Cancer Charity (UK). EHE patient advocacy groups from around the globe. provide content including research news, patient and fundraising stories, and much more. Click here to view the most recent edition of our online EHE newsletter, The Pledge.
Read More
New Study Uncovers Unexpected Role for AMPK in EHE
A project funded by the EHE Foundation, the EHE Rare Cancer Charity (UK), and the EHE Rare Cancer Foundation Australia, and led by Dr. Ryan Kanai in the Lamar Lab, was recently published in Cancers, revealing a surprising new role for AMPK in controlling the growth of EHE cells. Dr. Kanai set out to find […]
Read More
EHE Advocates Unite to Navigate Complexities of Drug Development
We are thrilled to share a new publication that includes participation of EHE advocacy organizations: “How to foster new treatment development in ultra-rare tumours? Joint EMA-EORTC multi-stakeholder workshops on ultra-rare sarcomas as a model for rare cancers.” Leaders of the EHE Rare Cancer Charity (UK), the EHE Foundation, and EHE ITALIA Associazione Non Solo Laura […]
Read More
Preclinical Evidence Supporting the Therapeutic Potential of Statins in EHE
In 2022, the EHE Foundation funded the Lamar Lab’s project entitled ‘Use of Pre-clinical EHE Models to Identify Druggable Pathways to Treat EHE,’ with the goal of identifying FDA-approved drugs that can be repurposed to treat EHE. By looking for drugs that are already FDA-approved, ideally, positive pre-clinical findings could be more rapidly translated to […]
Read More